Group 1 - China Regen Med (08158) announced a purchase agreement on January 2, 2026, where its wholly-owned subsidiary, China Regen (Hong Kong) Investment Co., will acquire 55% of the shares in Kangmeizhan Biotechnology Development Co., Ltd. for HKD 5,500 [1] - Following the acquisition, China Regen (Hong Kong) and China Star will hold 55% and 45% of Kangmeizhan's shares, respectively, with a shareholder agreement established to regulate their rights and obligations [1] - Kangmeizhan will operate as an investment holding company, focusing on investments in the Macau Special Administrative Region and collaborating with other strategic investors to manage clinic operations [1] Group 2 - The strategic cooperation aims to leverage the respective professional capabilities and resource advantages of the parties involved, enhancing the group's competitiveness in Macau through China Star's resources and business relationships [2] - Kangmeizhan will benefit from the group's industry resources and extensive experience in aesthetic medical and beauty services, achieving synergistic effects [2] - This strategic cooperation marks a significant milestone for the group in expanding into the new market of Macau, creating new market opportunities and commercial value for each company involved [2]
中国再生医学拟与China Star战略合作，收购康美赞55%股权